Skip to content

Our Board of Directors

Rob Michiels

Rob Michiels was elected as chairman of the Company's Board of Directors in 2016. He is a 30+-year veteran of the US medical device industry, both in corporate positions and as a serial start-up entrepreneur. He most recently served as CEO of CardiAQ™ Valve Technologies, a venture-funded start-up developing transcatheter mitral valve implantation that was acquired by Edwards Lifesciences in 2015.  He previously served as president and COO of CoreValve and as president and COO of InterVentional Technologies. He helped develop both companies from cardiovascular start-ups into established market leaders creating and marketing new and innovative interventional technologies that have strong synergies with the FEops story. Rob is also a founding partner of CONSILIUM Associates, a medical device market research company active in identifying, funding and greenhousing start-up technologies. Fluent in English, French and Dutch, he holds a bachelor's degree in economics from Antwerp University in Belgium and an MBA from Indiana University.

Alexandra Tolia

Alexandra Tolia is senior investment manager at PMV, where she directs investments in innovative life sciences ventures. Since 2011, she has served as a board member for several biotech companies, including eTheRNA, Multiplicom, FEops, iTeos Therapeutics and Apitope. Prior to PMV, she led investment strategy at Hunza Ventures, where she was instrumental in establishing the fund's biotech portfolio in Europe and the US. For over a decade before joining the investment industry, Alexandra built an international scientific track record, pioneering drug development initiatives in neurodegeneration and cardiovascular diseases, and managing key alliances between academia and the pharmaceutical industry. Alexandra holds a PhD in medical sciences from the University of Leuven, a degree in management from the Solvay Brussels School of Economics and Management and is the author of several high-impact scientific publications.

Marc Lambrechts

Marc Lambrechts is senior investment manager at Capricorn Venture Partners NV. Marc’s investment interests are related to technology fusion, specifically ICT, digital healthcare, IoT and nanotechnology. Marc oversaw successful investments in a.o., Enfocus, FillFactory and Punch Powertrain. He serves on the board of FEops, Bluebee and Leuven.Inc. Prior to joining Capricorn Venture Partners in March 1998, Marc served for six years as senior scientific adviser at IWT and worked for two years at the European R&D lab of Terumo Europe NV. Marc has a PhD in electrical engineering from the University of Leuven with a focus on implantable biosensors.

Matthieu De Beule

Under Matthieu’s leadership, FEops has transformed from a small academic spin-off into a fast-growing venture capital backed gazelle in the medtech sector. He completed his degree in engineering at the University of Ghent in 2002 and gained his PhD in 2008 for his research on cardiovascular device and procedure modeling. 

Guillaume Darnand

Guillaume is investment manager at Valiance, a London-based investment firm. He is responsible for its portfolio of life sciences companies, investing growth capital into innovative medical technologies in Europe and in the US. Prior to that, Guillaume worked in investment banking, advising large capitalization corporations on mergers and acquisitions and other corporate finance decisions, including capital market financing. He has experience in various sectors, including healthcare, consumer, retail, telecom, e-commerce and oil & gas. He graduated from ESSEC Business School in Paris.

Peter Mortier

Peter is internationally recognized for his groundbreaking work in the use of computer simulations to evaluate cardiovascular implants and procedures. Under his supervision, the TAVIguide™ tool has been transformed from an innovative idea into a CE-marked product. Peter has a PhD in biomedical engineering from Ghent University.

Tom Fleming

Tom worked with Boston Scientific Corporation for 21 years, most recently as VP and general manager of transcatheter aortic valves (TAVI) from 2012 – 2017. He was responsible for leading Boston Scientific into the global market for minimally invasive transcatheter aortic valves and was closely involved with the new business development strategy for the structural heart area. He holds a bachelor of science in business from the University of Minnesota, Minneapolis with concentration in marketing and logistics.